Pulmonary Cell News Volume 11.47 | Dec 01 2022

December 1, 2022

2022-12-01 | PULCN 11.47

Pulmonary Cell News by STEMCELL Technologies

Vol. 11.47 – 01 December, 2022

TOP STORY

CD147 Contributes to SARS-CoV-2-Induced Pulmonary Fibrosis

Investigators systemically analyzed lung pathogenesis in SARS-CoV-2- and its delta variant-infected humanized CD147 transgenic mice. Histopathology and transmission electron microscopy revealed inflammation, fibroblast expansion, and pronounced fibrotic remodeling in SARS-CoV-2-infected lungs.
[Signal Transduction and Targeted Therapy]

Full Article

Virtual Conference Exhibition: Pluripotent Stem Cells

PUBLICATIONSRanked by the impact factor of the journal

A Novel Mechanism for the Protection against Acute Lung Injury by Melatonin: Mitochondrial Quality Control of Lung Epithelial Cells Is Preserved through SIRT3-Dependent Deacetylation of SOD2

Researchers investigated whether melatonin could protect against sepsis-induced acute lung injury and lipopolysaccharide-treated lung epithelial cells through mitochondrial quality control as well as its possible molecular targets.
[Cellular and Molecular Life Sciences]

Abstract

Mitochondrial Citrate Accumulation Drives Alveolar Epithelial Cell Necroptosis in Lipopolysaccharide-Induced Acute Lung Injury

The authors examined mitochondrial citrate accumulation in alveolar epithelial cells that were challenged with lipopolysaccharide ex vivo and in vivo.
[Experimental & Molecular Medicine]

Full Article

Combination of Esomeprazole and Pirfenidone Enhances Antifibrotic Efficacy In Vitro and in a Mouse Model of TGFβ-Induced Lung Fibrosis

Investigators evaluated the anti-fibrotic efficacy of the proton pump inhibitor esomeprazole when combined with pirfenidone in vitro and in vivo.
[Scientific Reports]

Full Article

PRKCA Promotes Mitophagy through the miR-15a-5p/PDK4 Axis to Relieve Sepsis-Induced Acute Lung Injury

The protein kinase C-alpha (PRKCA)/miR-15a-5p/PDK4 axis alleviated acute lung injury caused by sepsis by promoting mitophagy and repressing anti-inflammatory response both in vivo and in vitro.
[Infection and Immunity]

Abstract

LUNG CANCER

NFκB Induces Epigenetic Repression of GPRC5A in Lung Epithelial Cells to Promote Neoplasia

Scientists showed that NF-κB acted as a transcriptional repressor in the suppression of GPRC5A. NF-κB induced GPRC5A repression both in vitro and in vivo.
[JCI Insight]

Abstract Graphical Abstract

The Roles of CPSF6 in Proliferation, Apoptosis and Tumorigenicity of Lung Adenocarcinoma

Researchers found that cleavage and polyadenylation specific factor 6 (CPSF6) was significantly higher expressed in tumor tissues than in normal tissues in multiple cancer types.
[Aging]

Full Article

Targeting BET Proteins Inhibited the Growth of Non-Small Cell Lung Carcinoma through Downregulation of Met Expression

Investigators found that JQ1, a bromodomain and extra terminal domain (BET) inhibitor, suppressed NSCLC cell growth, reduced the Met expression, and contributed to inactivation of PI3K/Akt and MAPK/ERK pathways.
[Cell Biology International]

Abstract

RNA m⁶A Methyltransferase METTL14 Promotes the Procession of Non-small Cell Lung Cancer by Targeted CSF1R

Researchers revealed the clinical significance of the N⁶-methyladenosine (m⁶A) RNA modification atlas, the function, and molecular targets CSF1R of METTL14 in NSCLC cell lines.
[Thoracic Cancer]

Full Article

Free Wallchart: Dynamic Modeling in Organoids

REVIEWS

SMARCA4: Current Status and Future Perspectives in Non-Small-Cell Lung Cancer

The authors describe the biological functions of SMARCA4 and its role in NSCLC development, metastasis, functional epigenetics, and potential therapeutic approaches for NSCLCs with SMARCA4 alterations.
[Cancer Letters]

Full Article

INDUSTRY AND POLICY NEWS

Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase IIa Study of AR-501 in Cystic Fibrosis Patients

Aridis Pharmaceuticals, Inc. announced the closing of patient enrollment in the multiple ascending doses and dose-ranging cohorts in the Phase IIa clinical trial of AR-501 in cystic fibrosis patients.
[Aridis Pharmaceuticals, Inc. (Globe Newswire)]

Press Release

FEATURED EVENT

Pulmonary Cell News Volume 11.47 | Dec 01 2022

CD147 Contributes to SARS-CoV-2-Induced Pulmonary Fibrosis

A Novel Mechanism for the Protection against Acute Lung Injury by Melatonin: Mitochondrial Quality Control of Lung Epithelial Cells Is Preserved through SIRT3-Dependent Deacetylation of SOD2

Mitochondrial Citrate Accumulation Drives Alveolar Epithelial Cell Necroptosis in Lipopolysaccharide-Induced Acute Lung Injury

Combination of Esomeprazole and Pirfenidone Enhances Antifibrotic Efficacy In Vitro and in a Mouse Model of TGFβ-Induced Lung Fibrosis

PRKCA Promotes Mitophagy through the miR-15a-5p/PDK4 Axis to Relieve Sepsis-Induced Acute Lung Injury

NFκB Induces Epigenetic Repression of GPRC5A in Lung Epithelial Cells to Promote Neoplasia

The Roles of CPSF6 in Proliferation, Apoptosis and Tumorigenicity of Lung Adenocarcinoma

Targeting BET Proteins Inhibited the Growth of Non-Small Cell Lung Carcinoma through Downregulation of Met Expression

RNA m⁶A Methyltransferase METTL14 Promotes the Procession of Non-small Cell Lung Cancer by Targeted CSF1R

SMARCA4: Current Status and Future Perspectives in Non-Small-Cell Lung Cancer

Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase IIa Study of AR-501 in Cystic Fibrosis Patients

Infections in Pregnancy: Pathogenic Mechanisms, Experimental Advances and Clinical Strategies

> See All Events

Postdoctoral Position – Pulmonary Immunology

Research Associate – Pulmonary

Postdoctoral Scientist – Lung Epithelial Stem and Progenitors Cells

PhD Position – Precision Medicine in Cystic Fibrosis

Senior Program Associate – Science in the City

> See All Jobs